Eidos Therapeutics initiated with a Buy at BTIG. BTIG analyst Thomas Shrader initiated Eidos Therapeutics with a Buy rating and a $38 price target, saying that most of Eidos’ stock growth over the next two years is “likely to result from appreciation of the TTR market size… and AG10’s attractive properties.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.